March 4, 2024 5:21pm

As there was no bait on the portfolio hook today

Pre-open Indications: 1 Hit and 6 Miss

Harvard Apparatus RT (OTCQB: HRGN) dived precariously -$0.69 (was -$0.99 or -26.40%) or -18.40% to $3.08 with 10,409 shares traded

Subscription is coming; a “buck” a day will keep your portfolio in play - be a subscriber to continue reading!

A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio defense. The Bottom Line includes earnings and “whispers”!

Never leave an investor uninformed! A trusted source of factual reporting!

I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others will not say or write about – facts in evidence! 

 

Monday: The Dow closed DOWN -97.55 points or -0.25%, the S&P closed DOWN -=6.13 points -0.12% while the Nasdaq closed DOWN -67.43 points or -0.41%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Monday’s losses come as the market has largely raced higher over the past several weeks …

Cell and gene therapy equities and market indexes retreated Monday, pushing the S&P 500 and Nasdaq off the cliff and all-time highs.

 

Pre-open Indication: 1 Hit <Editas Medicine (EDIT -$0.61)> and 6 MISS < AxoGen (AXGN -0.10), Blueprint Medicine (BPMC -$4.32), CRISPR Therapeutics (CRSP -$2.01), Intellia Therapeutics (NTLA -$0.27), BioLife Solutions (BLFS +$0.18), Voyager Therapeutics (VYGR +$0.20)>

 

52-week low:

  • uniQure NV (QURE) at $5.13

 

Monday’s RegMed Investors’ (RMi) opening bell: “while fishing in the sea of portfolio equities, reel-in your nets. You will always need to cull the catch.” … https://www.regmedinvestors.com/articles/13354

 

Advance/Decline (A/D) Line:

  • Monday’s advance/decline line at the open was negative with 10 incliner, 23 decliners and 2 flats; ending with a negative close of 10 incliners, 24 decliners and 1 flat

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q1/24: March, 1 positive and 1 negative closes

  • February, 1 holiday, 9 negative and 11 positive closes
  • January: 2 holiday, 12 negative and 8 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Monday, the IBB was down -0.93% and the XBI was down -0.79%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Monday was up +0.38 point or +2.90% at 13.49

 

Monday’s Closing Down (10 of 24):

  • Blueprint Medicine (BPMC -$4.32 after Friday’s +$1.60),
  • Alnylam Pharmaceuticals (ALNY -$2.57 after Friday’s +$1.52),
  • CRISPR Therapeutics (CRSP -$2.01 after Friday’s -$0.47),
  • Beam Therapeutics (BEAM -$1.60),
  • Harvard Apparatus RT (OTCQB: HRGN -$0.69),
  • Fate Therapeutics (FATE -$0.66 after Friday’s +$0.65),
  • Editas Medicine (EDIT -$0.61 after Friday’s +$0.47
  • Ionis Pharmaceuticals (IONS -$0.59),
  • Verve Therapeutics (VERV -$0.45),
  • uniQure NV (QURE -$0.43 after Friday’s -$0.16),

Flat (1):

  • Adverum Biotechnologies (ADVM)

Monday’s Closing Up (10 of 10):

  • Voyager Therapeutics (VYGR +$0.20 after Friday’s +$1.12)
  • BioLife Solutions (BLFS +$0.18 after Friday’s +$1.07),
  • Regenxbio (RGNX +$0.17 after Friday’s +$3.75)
  • Generation Bio (GBIO +$0.14),
  • Compass Therapeutics (CMPX +$0.08),
  • Vericel (VCEL +$0.06 after Friday’s -$0.97
  • Prime Medicine (PRME +$0.03),
  • Agenus (AGEN +$0.022 after Friday’s -$0.0099),
  • Brainstorm Cell Therapeutics (BCLI +$0.0198 after Friday’s -$0.0218

Mesoblast (MESO +$0.01),

 

Q1/24 – March

(3/4) Monday closed negative with 6 incliners, 27 decliners and 2 flats

(3/1) Friday closed positive with 23 incliners, 10 decliners and 2 flats

 

The BOTTOM LINE: The cell and gene therapy sector closed today down after Friday’s closed positive …

Earnings, net losses, and per-share losses, runways and guidance have begun Q4 and FY23 which WILL be crucial to continue downside force in the sector as history has taught us i.e., investors.

I have seen 4 net income for the Q4 and FY23 - MiMedx (MDXG) and Voyager Therapeutics (VYGR) followed by Q4 CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM) <but each had a FY23 loss>

19 have reported …

RegMed Investors (RMi) - Q4/23 & FY23 Cell and Gene Therapy Earnings Scorecard Results https://www.regmedinvestors.com/articles/11628

 

 I ALSO reiterate, “Don't chase the cell and gene therapy sector, especially with the Nasdaq extended.”

Short and non-sweet: SELL into STRENGTH – accumulate some “powder” i.e., cash!

  • Should have taken MY own advice today!!!

 

The top three (3) performing in the session:

  • Monday: Voyager therapeutics (VYGR), BioLife Solutions (BLFS) and Regenxbio (RGNX) The worst three (3) in the session:  
  • Monday: CRISPR Therapeutics (CRSP), Blueprint Medicine (BLMC) and Alnylam Pharmaceuticals (ALNY)

 

BEWARE… How MANY TIMES AM I RIGHT … MORE than MOST!!

The Harvard Apparatus RT (OTC QB HRGN) formerly the Biostage (BSTG) Chronicles: shows how the “pimp/pump and promote” works …my treatise is VALIDATED!

  • (3/4) Monday closed down -$0.69 with 10,409 shares traded (aver 3-mo= 2,765 shares)
  • (3/1) Friday closed up +$0.05 with 15,125 shares traded
  • Thursday closed down -$0.05 with 301 shares traded
  • Wednesday closed up +$0.05 WITH 12,187 shares traded (aver 3-mo=2,311 shares)
  • Tuesday dropped -$0.01 with 1,314 shares traded,
  • (2/26) Monday closed down -$0.09 with 350 shares traded

Did you notice how it barely trades unless volume is being “pumped.”  This question needs to be answered as HRGN is desperate to finance by any means as past Chinese private placement investors must be feeling … WHAT … TAKEN to the cleaners?

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.